

**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
 Witness Disclosure Requirement – “Truth in Testimony”  
 Required by House Rule XI, Clause 2(g)(5)

|  |                                   |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
|--|-----------------------------------|----------------|------------------------------|-------------------------|-----------|--------------|--|--|---------------------------|-----------------------------------|-------|---------------|--|--|----------------------------|------------------|-----------|----------|---|--|
| <b>1. Your Name:</b><br>Lee H Schwamm, MD  |                                   |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| <b>2. Your Title:</b><br>Senior Volunteer Leader, American Heart Association<br><br>Academic Health System Title:<br>Sr Vice President and Chief Digital Health Officer, Yale New Haven Health System<br>Associate Dean, Digital Strategy & Transformation, Professor of Neurology, Yale School of Medicine  |                                   |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| <b>3. The Entity(ies) You are Representing:</b><br>American Heart Association  |                                   |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| <b>4. Are you testifying on behalf of the Federal, or a State or local government entity? (If “Yes,” skip Item 5 and Item 6.)</b>  | <b>Yes</b>                        | <b>No</b><br>x |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| <b>5. Grants, Contracts, and Payments</b>  |                                   |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| <p><b>a. Please list any <u>Federal grants or contracts</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2021</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b></p> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; padding-bottom: 5px;">U24NS107243 (Schwamm, PD/PI)</td> <td style="width: 50%; padding-bottom: 5px;">08/01/2018 – 07/31/2023</td> </tr> <tr> <td style="padding-bottom: 5px;">NIH-NINDS</td> <td style="padding-bottom: 5px;">\$ 2,399,875</td> </tr> <tr> <td colspan="2" style="padding-bottom: 10px;">New England Regional Coordinating Center for the NINDS Stroke Trials Network<br/>This integrated team of hospitals and EMS agencies in Boston and Western Massachusetts that will develop new translational science and successfully execute the NINDS Stroke Trials Network Phase 1,2 and 3 studies. Role: PD/PI</td> </tr> <tr> <td style="padding-bottom: 5px;">R-1609-35995, (Temel, PI)</td> <td style="padding-bottom: 5px;">12/01/17-11/30/22 (NCE to 4/2025)</td> </tr> <tr> <td style="padding-bottom: 5px;">PCORI</td> <td style="padding-bottom: 5px;">\$ 11,108,640</td> </tr> <tr> <td colspan="2" style="padding-bottom: 10px;">Comparative Effectiveness of Early Integrated Telehealth Versus In-Person Palliative Care for Patients with Advanced Lung Cancer. The long-term objective of this multi-center randomized trial is to compare two delivery models of early integrated palliative and oncology care.<br/>Role: Lead TeleHealth Co-Investigator</td> </tr> <tr> <td style="padding-bottom: 5px;">R01NS111952 (Mehrotra, PI)</td> <td style="padding-bottom: 5px;">04/01/19-3/31/23</td> </tr> <tr> <td style="padding-bottom: 5px;">NIH/NINDS</td> <td style="padding-bottom: 5px;">\$76,788</td> </tr> <tr> <td colspan="2" style="padding-bottom: 10px;">The Impact of Telestroke on Patterns of Care and Long-Term Outcomes<br/>Many patients with a stroke, in particular those in rural communities, receive care at an emergency department that does not have a stroke expert and therefore they may not receive life-saving reperfusion. Telestroke is one potential solution; with</td> </tr> </table> |                                   |                | U24NS107243 (Schwamm, PD/PI) | 08/01/2018 – 07/31/2023 | NIH-NINDS | \$ 2,399,875 | New England Regional Coordinating Center for the NINDS Stroke Trials Network<br>This integrated team of hospitals and EMS agencies in Boston and Western Massachusetts that will develop new translational science and successfully execute the NINDS Stroke Trials Network Phase 1,2 and 3 studies. Role: PD/PI |  | R-1609-35995, (Temel, PI) | 12/01/17-11/30/22 (NCE to 4/2025) | PCORI | \$ 11,108,640 | Comparative Effectiveness of Early Integrated Telehealth Versus In-Person Palliative Care for Patients with Advanced Lung Cancer. The long-term objective of this multi-center randomized trial is to compare two delivery models of early integrated palliative and oncology care.<br>Role: Lead TeleHealth Co-Investigator |  | R01NS111952 (Mehrotra, PI) | 04/01/19-3/31/23 | NIH/NINDS | \$76,788 | The Impact of Telestroke on Patterns of Care and Long-Term Outcomes<br>Many patients with a stroke, in particular those in rural communities, receive care at an emergency department that does not have a stroke expert and therefore they may not receive life-saving reperfusion. Telestroke is one potential solution; with |  |
| U24NS107243 (Schwamm, PD/PI)   | 08/01/2018 – 07/31/2023           |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| NIH-NINDS  | \$ 2,399,875                      |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| New England Regional Coordinating Center for the NINDS Stroke Trials Network<br>This integrated team of hospitals and EMS agencies in Boston and Western Massachusetts that will develop new translational science and successfully execute the NINDS Stroke Trials Network Phase 1,2 and 3 studies. Role: PD/PI   |                                   |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| R-1609-35995, (Temel, PI)  | 12/01/17-11/30/22 (NCE to 4/2025) |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| PCORI  | \$ 11,108,640                     |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| Comparative Effectiveness of Early Integrated Telehealth Versus In-Person Palliative Care for Patients with Advanced Lung Cancer. The long-term objective of this multi-center randomized trial is to compare two delivery models of early integrated palliative and oncology care.<br>Role: Lead TeleHealth Co-Investigator   |                                   |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| R01NS111952 (Mehrotra, PI)   | 04/01/19-3/31/23                  |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| NIH/NINDS  | \$76,788                          |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |
| The Impact of Telestroke on Patterns of Care and Long-Term Outcomes<br>Many patients with a stroke, in particular those in rural communities, receive care at an emergency department that does not have a stroke expert and therefore they may not receive life-saving reperfusion. Telestroke is one potential solution; with  |                                   |                |                              |                         |           |              |  |  |                           |                                   |       |               |  |  |                            |                  |           |          |   |  |

telestroke a stroke expert who is physically far away guides a local physician through the decision-making process via videoconference. In this project, our goal is to understand the impact of telestroke on where patients get care, likelihood of dying, disability, and the experience of front-line physicians and nurses.

Role: Co-Investigator

1R01AG079887-01A1 (Zachrison, PI)

07/2023 - 06/2028

NIH/NIA

\$3,722,209

Addressing Racial/Ethnic Disparities in Stroke Care Access Using Hospital Transfer Networks

Our goal is to understand the role that interhospital transfer processes play in contributing to disparities in access and outcomes for stroke patients, and to identify solutions to ensure better access and outcomes for stroke patients of all races and ethnicities.


Role: Co-Investigator

- b. Please list any contracts or payments originating with a foreign government that you or the entity(ies) you represent have received on or after January 1, 2021. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.

-None

|   |     |         |
|---|-----|---------|
| 6. Are you a fiduciary (i.e., authorized to act on behalf of or for the benefit of) for any entity that has an interest in the subject matter of the hearing? | Yes | No<br>X |
|---|-----|---------|

7. Please attach your curriculum vitae to your completed disclosure form.

Signature:  \_\_\_\_\_

Date: 4/8/2024 \_\_\_\_\_

#### INSTRUCTIONS FOR COMPLETING THE TRUTH-IN-TESTIMONY DISCLOSURE FORM

**In General.** The attached form is intended to assist witnesses appearing before the Committee on Energy and Commerce in complying with Rule XI, clause 2(g)(5) of the Rules of the House of Representatives, which provides:

(B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include—(i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts,

grants, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing. (C) The disclosure referred to in subdivision (B)(ii) shall include—(i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government. (D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

**Please complete the form in accordance with these directions.**

1. **Name (Item 1 on the form).** Please provide the name of the witness.
2. **Title (Item 2 on the form).** Please provide the title of the witness.
3. **Entity(ies) (Item 3 on the form).** Please identify the entity(ies) on whose behalf the witness is testifying.
4. **Governmental Entity (Item 4).** Please check the box indicating whether or not the witness is testifying on behalf of a government entity, such as a Federal department or agency, or a State or local department, agency, or jurisdiction. Trade or professional associations of public officials are not considered to be governmental entities. If you answer “Yes” to Item 4, please skip Item 5.a, Item 5.b, and Item 6.
5. **Grants and Contracts**
  - a. **(Item 5.a).** Please list any Federal grants or contracts that you or the entity(ies) you represent have received on or after January 1, 2021. For each such grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing, please include the amount and source of each. Only grants, contracts, or payments related to the hearing must be listed.
  - b. **(Item 5.b).** Please list any contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2021. For each such contract or payment related to the subject matter of the hearing, please include the amount and country of origin. Only grants, contracts, or payments related to the hearing must be listed.
6. **Fiduciary Capacity (Item 6).** Please check the box indicating whether or not the witness is a fiduciary of **any** organization or entity with an interest in the subject matter of the hearing. This includes, but is not limited to, serving as a director, officer, advisor, or resident agent of an entity with an interest in the hearing.
7. **Curriculum Vitae (Item 7).** Please attach your CV to your completed disclosure form.
8. **Submission.** Please sign and date the form in the appropriate place. Please submit this form with your written testimony. Please note that under the Committee’s rules, copies of a written statement of your proposed testimony must be submitted before the hearing commencements. To the greatest extent practicable, please also provide a copy in electronic format according to the accompanying Electronic Format Guidelines.